Limonene for Pulmonary Nodule Chemoprevention

Phase 2

Recruiting

• Conditions: Pulmonary Nodules
• Interventions: Drug: Limonene capsule; Drug: Limonene capsules(Placebo)

• Registration Number: NCT05525260
• Lead Sponsor: Shanghai Jiao Tong University School of Medicine

Brief Summary

The prevention and treatment of lung nodules involves many fields in preventive medicine and clinical medicine. A nodule is a growth or lump that may be malignant (cancer) or benign (not cancer). This study is aim to investigate the chemopreventive effect of limonene in inhibiting the occurrence/progression of ground glass pulmonary nodules. It is expected that limonene can be used as a safe and effective chemopreventive agent for preventing the development/progress of pulmonary nodules as well as expanding the indications of limonene.

Detailed Description

Early prevention, early detection and early treatment of lung cancer can help reduce the incidence and improve the survival rate.Chemoprevention is known to have an important role in high-risk people because it has the potential to prevent or reverse the progression of lung cancer.Lung nodules are good targets for testing the efficacy of chemopreventive agents.So far，none of the chemopreventive agents have been shown to be effective.

Limonene is widely found in the essential oils of traditional Chinese medicine tangerine peel, green peel and other plants. Its taste is sour, sweet and pungent. It has an aromatic odor effect. Limonene Capsule, a Chinese patent medicine, has been on the market, which is suitable for the treatment of cholecystitis, cholangitis, cholelithiasis, and postoperative biliary syndrome.Preliminary studies of the research group suggest that it has a potential anti-cancer effect.

This randomized, double-blind, controlled trial studied limonene compared with placebo in treating high-risk patients with pure ground glass pulmonary nodules，so as to expand indications.

Study Timeline

• Study First Submitted: 2022-08-09
• Study First Submitted QC: 2022-08-30
• Study First Posted: 2022-09-01
• Status Verified: 2023-02
• Study Start: 2023-02
• Last Update Submitted: 2023-02-02
• Last Update Posted: 2023-02-06
• Primary Completion: 2024-02
• Study Completion: 2025-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 160

Inclusion Criteria

• Non-smokers (those who have smoked less than 100 cigarettes in their lifetime, including those who have never smoked in their lifetime).
• Subjects must have positive nodules detected by high-resolution CT（HRCT）: longest diameter > 6 mm and < 20 mm; pure ground glass nodule; according to the judgment of the clinician, follow-up can be performed, and surgical excision is not recommended for the time being; the nodules did not disappear or were not significantly reduced by more than 2 mm after six months follow-up; subjects should have at least one positive nodule when had multiple nodules.
• ECOG performance status 0-1.
• Those who accept and are willing to sign the informed consent.

Exclusion Criteria

• Subjects with the history of autoimmune diseases and severe gastrointestinal diseases;

• Subjects suffering from malignant tumor, severe heart disease, severe liver or kidney disease currently or within the past 5 years;

• Within 6 weeks since prior herbal supplements, non-steroidal anti-inflammatory drugs, or antibiotics

• Subjects who are allergic to limonene capsules or citrus foods;

• Use of any other investigational agents at time of enrollment in the study during the three months preceding study enrollment

• Pregnant or lactating females, or those who disagreeing with contraception;

• Subjects who have a history of mental illness and cannot cooperate with this project;

• HIV-positive subjects should be excluded.

• Subjects whose organ and bone marrow function indexes exceeded the following range of normal value were excluded:

  1. Leukocytes: 3.5-9.5 109/L;
  2. Absolute neutrophil count: 1.8-6.3 109/L;
  3. Platelets: 125-350 109/L;
  4. Total bilirubin: 5.0-21.0 µmol /L;
  5. AST (SGOT)/ALT (SGPT): 0.8-1.5;
  6. Serum creatinine: 41-81 μmol/L;

• Other situations where the researcher thinks it is inappropriate to participate in this research.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Limonene capsules(marketed product in China)	Limonene capsule	Limonene capsules(marketed product in China) donate by pharmaceutical company.
Limonene capsules(Placebo)	Limonene capsules(Placebo)	Same smell, color and shape as limonene capsules(marketed product in China), without limonene in capsules.

Primary Outcome Measures

Name	Time	Method
Changes in the sum of longest diameters of target nodules (multiple nodules) between the drug group and the placebo group.	at baseline, three months and six months after administration	Difference in the sum of longest diameters of target nodules

Secondary Outcome Measures

Name	Time	Method
Overall response rate of participants as measured by RECIST criteria between the two groups	at baseline, three months and six months after administration	Difference in the overall response rate of participants
Changes in the sum of longest diameters of baseline target nodules (multiple nodules) between the drug group and the placebo group	at baseline and twelve months after administration	Difference in the sum of longest diameters of target nodules
Change in density of baseline target nodules between the two groups.	at baseline, three months and six months after administration	Difference in density of baseline target nodules
Change in density of baseline non-target nodules between the two groups	at baseline, three months and six months after administration	Difference in density of baseline non-target nodules
Adverse events	at baseline, three months and six months after administration	Incidence of adverse events
Cytokine detection	at baseline, three months and six months after administration	Value of cytokine detection
Change in diameters of baseline target nodules (single nodule) detected by CT between the two groups.	at baseline, three months and six months after administration	Difference in the longest diameters of baseline target nodules
Change in the longest diameters size of baseline non-target nodules between the two groups	at baseline, three months and six months after administration	Difference in the longest diameters of baseline non-target nodules
Change in numbers of baseline non-target nodules between the two groups	at baseline, three months and six months after administration	Difference in numbers of baseline non-target nodules
Value of serum miRNA	at baseline, three months and six months after administration	Value of serum miRNA
Plasma metabolomics	at baseline, three months and six months after administration	Analysis of plasma metabolomics
Proportion of circulating blood immune cells	at baseline, three months and six months after administration	Analysis of the proportion of circulating blood immune cells

Trial Locations

Locations (1)

Shanghai Chest Hospital; 🇨🇳 Shanghai, Shanghai, China